The high-dose quadrivalent influenza vaccine is an inactivated vaccine indicated for the prevention of influenza and reduction of hospitalization due to influenza-related pneumonia in elderly individuals aged 65 years and older, with the following characteristics:
- Has been used for over 10 years in the United States and Europe
- Contains an antigen amount that stimulates the immune response up to 4 times higher
- Has an increased effectiveness in preventing influenza by up to 24% compared to the standard dose vaccine
- Can significantly reduce hospitalization rates from various complications caused by influenza, thereby further reducing hospitalization rates from the following causes:
- Increased pneumonia cases by 27.3%
- Increased heart and respiratory disease cases by 17.9%
- Increased influenza cases by 11.7%
- Increased cases from all causes related to influenza infection by 8.4%
Safety and Care After Vaccination
Most vaccines currently in use are highly safe, but some side effects can still occur, which are mostly mild and acceptable, and symptoms usually resolve within 2-3 days. To date, more than 202 million doses of the high-dose influenza vaccine have been administered worldwide, and safety monitoring in vaccine recipients globally has found no safety concerns.
The most common adverse reactions after vaccination are pain at the injection site, muscle pain, headache, and general discomfort, which typically occur within the first 3 days after vaccination and usually resolve within 3 days.
